The content of this presentation is provided to an audience of international healthcare professionals from around the world for scientific discussion and scientific exchange. Bayer does not recommend the use of any drug substance outside of its approved indications.

At the moment of publication, the compound presented has been only approved by Food and Drug Administration (FDA) and European Medicines Agency (EMA). For other approvals, follow your local regulations or health authorities legislation.

European Association for the Study of DiabetesIndustry Symposium PresentationsSeptember 19–23, 2022

Presentations of the Bayer Industry Symposium at the European Association of the Study of Diabetes 58th Annual Meeting 2022

Thank you for your interest! Please see below to download the presentations from the Bayer Industry Symposia at the EASD Congress 2022.

Access to the slides will be available after their presentation at the congress.

Finerenone

Wednesday 21 September, 2022 | 18:45–19:45 CEST
EASD 2022 Industry Symposium

Nonsteroidal MRAs in CKD and T2D: Current knowledge and practical insights

Session type: Industry SymposiumSpeaker: Peter Rossing (chair), Janet McGill & Magnus Löndahl

Doc Icon

Download the Slide Deck

Thursday 22 September, 2022 | 18:30–19:30 CEST
EASD 2022 Industry Symposium

Nonsteroidal MRAs in patients with CKD and T2D: What is next for finerenone?

Session type: Industry SymposiumSpeaker: Samy Hadjadj (chair), Hiddo Heerspink, Paola Fioretto & Christoph Wanner

Doc Icon

Download the Slide Deck

The compendium provided by Bayer is a compilation of Bayer-sponsored presentations. Copies of presentations obtained from this compendium are for personal use only and may not be reproduced or distributed without permission from European Association for the Study of Diabetes (EASD) and from the authors.

Reused with permission. © 2022 European Association for the Study of Diabetes (EASD). All rights reserved.

For any questions, please contact Medical Information at 1-888-84-BAYER (1-888-842-2937), or visit go.bayer.com/vPIR.

MA-M_FIN-ALL-0921-1

© 2022 Bayer AG

The content of this presentation is provided to an audience of international healthcare professionals from around the world for scientific discussion and scientific exchange. Bayer does not recommend the use of any drug substance outside of its approved indications.

 

At the moment of publication, the compound presented has been only approved by the Food and Drug Administration (FDA) and European Medicines Agency (EMA). For other approvals, follow your local regulations or health authorities legislation.

 

Last updated on 27/09/2022